BMO Capital Adjusts Price Target on Vertex Pharmaceuticals to $566 From $500
Vertex Pharmaceuticals (VRTX) has an average outperform rating and a price target range of $325 to $589, according to analysts polled by Capital IQ.Price: 490.21, Change: +2.09, Percent Change: +0.43
Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Vertex Pharmaceuticals Price Target Raised to $500.00/Share From $462.00 by HC Wainwright & Co.
Vertex Pharmaceuticals Price Target Raised to $500.00/Share From $462.00 by HC Wainwright & Co.
Vertex Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/19/2024 2.43% HC Wainwright & Co. $462 → $500 Maintains Buy 07/11/2024 -6.79% Morgan Stanley $402 → $45
H.C. Wainwright Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $500
H.C. Wainwright analyst Andrew Fein maintains $Vertex Pharmaceuticals(VRTX.US)$ with a buy rating, and adjusts the target price from $462 to $500.According to TipRanks data, the analyst has a
Express News | Vertex Pharmaceuticals Inc. : H.c. Wainwright Raises Target Price to $500 From $462
Express News | Vertex Pharmaceuticals Inc : JP Morgan Raises Target Price to $505 From $450
Vertex Pharmaceuticals Hits All-time High
Vertex Pharmaceuticals, Genomics Extend Drug Discovery, Development Collaboration by 3 Years
Vertex Pharmaceuticals (VRTX) and Genomics are extending their collaboration by three years to discover and develop precision medicines using genetics and machine learning, Genomics said Tuesday.The
Express News | Genomics PLC - Three-Year Extension of Collaboration to Use Genomics to Accelerate Drug Discovery
Express News | Genomics PLC Announces New Extension and Expansion of Drug Discovery Collaboration With Vertex
Express News | Orum Therapeutics - to Receive $15 Mln Upfront Payment, up to $310 Mln in Potential Option Fees, Milestone Payments per Target Plus Tiered Royalties
Express News | Orum Therapeutics-Global, Multi-Target License, Option Agreement With Vertex for Use of Orum's Tpd² Technology to Develop Degrader-Antibody Conjugates
Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $589 From $577, Maintains Buy Rating
Vertex Pharmaceuticals (VRTX) has an average outperform rating and a price target range of $325 to $577, according to analysts polled by Capital IQ.Price: 495.49, Change: +4.64, Percent Change: +0.95
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider
Vertex Pharmaceuticals (VRTX) closed at $490.85 in the latest trading session, marking a +0.43% move from the prior day.
Express News | Vertex Seeks Court Confirmation That Financial Support Program For Fertility Services Related To Casgevy Does Not Violate Federal Anti-Kickback Laws; Disagrees With Regulator's Conclusion And Seeks Federal Court Ruling
Express News | Vertex Disagrees With the Regulator's Conclusion That the Program Would Implicate Anti-Kickback Laws, and Wants a Federal Court to Rule Otherwise
Express News | Vertex Is Seeking Confirmation That Its Program for Providing Financial Support for Fertility Services Related to Casgevy Would Not Violate Federal Anti-Kickback Laws
Express News | Vertex Pharmaceuticals Sues U.S. Department of Health and Human Services in Connection With Casgevy Gene Editing Therapy